Company profile: Metagenomi
1.1 - Company Overview
Company description
- Provider of an AI- and metagenomics-driven discovery platform to uncover novel genome editing systems for therapeutics development and a comprehensive gene editing toolbox, including programmable nucleases, base editors, RNA- and DNA-mediated integration systems, ultra-small systems deliverable via single AAV for organ targeting, and RNA Mediated Integration Systems for small and large programmable genomic edits.
Products and services
- Gene Editing Toolbox: A modular portfolio comprising programmable nucleases, base editors, and RNA- and DNA-mediated integration systems for diverse genetic modifications, enabling site-specific breaks and single-nucleotide changes
- Ultra-Small Systems: Highly efficient, single-AAV-deliverable genome editing systems engineered for organ targeting, compact enough for delivery via a single AAV to target organs
- Discovery Platform: An ML-driven platform that leverages artificial intelligence and metagenomics to uncover novel genome editing tools from natural environments for therapeutics development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Metagenomi
Reverie Labs
HQ: United States
Website
- Description: Provider of machine learning-driven preclinical drug development solutions, applying supervised deep learning, virtual screening, computational chemistry, and algorithmic molecular generation for lead discovery and optimization. Offers molecular property prediction (on-target binding, toxicity, ADMET), rich representations for small molecules and proteins, and a pipeline of wholly-owned and partner-developed drug candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverie Labs company profile →
360 Vantage
HQ: United States
Website
- Description: Provider of cloud-based CRM, sales force automation, and closed-loop marketing systems for the life sciences industry, offering 360 CRM, 360 CLM, compliance and e-learning solutions, along with a full suite of professional and managed services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 360 Vantage company profile →
System Analytic
HQ: United Kingdom
Website
- Description: Provider of an ecosystem of innovative digital tools and world-class services to support the entire KOL/HCP engagement cycle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full System Analytic company profile →
Ovation
HQ: United States
Website
- Description: Provider of a cloud-based LIMS for molecular diagnostic laboratories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ovation company profile →
RxData
HQ: United States
Website
- Description: Provider of a global market access data platform offering on-demand, automated pharmaceutical pricing and reimbursement insights. Solutions include comprehensive market access intelligence, exportable dashboards, real-time monitoring of 100+ sources, curated HTA/regulatory data, visible net price algorithms, and an internal data repository.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RxData company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Metagenomi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Metagenomi
2.2 - Growth funds investing in similar companies to Metagenomi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Metagenomi
4.2 - Public trading comparable groups for Metagenomi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →